Evommune targets $159M raise in IPO

Evommune, a Palo Alto-based biotech focused on autoimmune diseases, aims to raise as much as $159 million in its IPO, at a $511 million valuation.

Why it matters: It's the third biotech company to test public markets after a half-year drought.